8-K: Renalytix Upsizes Equity Placing to $12 Million, Extends Cash Runway

Renalytix plc successfully completed an upsized equity placing, raising approximately $12 million to extend its cash runway into Q4 2024.

Summary

• Renalytix plc has successfully completed an equity placing, raising approximately $12 million.
• The placing involved the issuance of 46,801,872 new ordinary shares at a price of 20 pence per share.
• The gross proceeds from the placing are expected to extend the company's cash runway into calendar Q4 2024.
• The placing was conducted with both UK and US institutional investors.
• The issuance of shares is split into two tranches, with the first tranche of 19,986,031 shares expected to close around March 14, 2024.
• The second tranche is conditional upon shareholder approval at a general meeting.
• The company's enlarged issued ordinary share capital will be 119,916,187 following the first closing.
• The company will file resale registration statements with the SEC within 45 days of each closing to register the ordinary shares issued in each tranche.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the successful capital raise and extended cash runway. However, the need for further financing and the conditional nature of the second tranche introduce some caution.

Positives

• The successful equity placing provides Renalytix with additional capital.
• The extended cash runway into Q4 2024 provides the company with more financial stability.
• The participation of both UK and US institutional investors indicates confidence in the company.
• The company is taking steps to ensure the shares can be traded freely after the restrictions are removed.

Negatives

• The second tranche of the placing is conditional on shareholder approval, which introduces some uncertainty.
• The company's current cash runway, without the placing, only extends to April 2024, indicating a need for immediate funding.

Risks

• The second tranche of the placing is dependent on shareholder approval, which may not be obtained.
• The company's cash runway is still limited, even with the proceeds of the placing, and further financing may be required.
• The company is subject to market conditions and the acceptance of its novel AI technologies.
• The company has only recently commercially launched KidneyIntelX, and its success is not guaranteed.

Future Outlook

The company expects the net proceeds from the placing to extend its cash runway into calendar Q4 2024 and reserves the right to explore further financing options while the formal sale process is underway.

Management Comments

• The company reserves the right to continue to explore, and undertake, if appropriate, further financing or financings following this transaction in order to further extend the cash runway while the previously announced Formal Sale Process is underway.
• Such financings may consist of equity and/or debt or convertible securities.

Industry Context

This announcement comes as Renalytix continues to develop and commercialize its KidneyIntelX technology, a novel approach to kidney disease risk assessment. The capital raise will support the company's ongoing operations and growth initiatives in the competitive diagnostics market.

Comparison to Industry Standards

• The equity placing is a common method for biotech companies to raise capital, especially those in the early commercialization phase like Renalytix.
• Comparable companies in the diagnostics space, such as Exact Sciences and Guardant Health, have also utilized equity financings to fund their growth.
• The size of the raise, $12 million, is relatively small compared to some larger biotech financings, but is appropriate for a company of Renalytix's size and stage.
• The use of a two-tranche structure with a shareholder approval requirement for the second tranche is also a common practice to manage dilution and ensure compliance with listing rules.

Related Party Transactions

• Christopher Mills and/or certain investment vehicles connected with him have subscribed for certain Placing Shares.
• Mount Sinai has also subscribed for certain Placing Shares.
• The Directors who are independent of the related party transaction consider the terms of the participation of those related parties to be fair and reasonable insofar as Shareholders are concerned.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The extended cash runway provides more stability for employees and suppliers.
• The capital raise will support the company's ability to continue developing and commercializing its products, which could benefit customers.

Next Steps

• The company will seek shareholder approval for the second tranche of the placing at a general meeting.
• The company will file resale registration statements with the SEC within 45 days of each closing.
• The company will continue to explore further financing options.

Key Dates

Keywords

equity placing, capital raise, cash runway, ordinary shares, institutional investors, KidneyIntelX, shareholder approval, resale registration, working capital, bioprognosis